Nav: Home

Integrated lead discovery: An evolving toolbox

June 15, 2018

A new SLAS Discovery review article by GlaxoSmithKline researchers in the U.S. and U.K. offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.

While high-throughout screening (HTS) remains a mainstay in drug discovery, other approaches have emerged or evolved in the past decade that offer complementary strengths and weaknesses, and are increasingly applied in combination with, or in lieu of, HTS. Great success often can be achieved by combining different approaches in an integrated manner.

Leveridge et al. survey the landscape of lead discovery tactics that researchers use today and explain how this toolbox of approaches is evolving as new science emerges, such as in the areas of complex cellular models and computational techniques. Case studies illustrate how integration of techniques like DNA-encoded library screening (ELT) and HTS, phenotypic and target-based screening, and virtual screening (VS) with experimental approaches can lead to successful outcomes and provide insights and synergies that would never have been obtained through one technique alone.
-end-
"Integration of Lead Discovery Tactics and the Evolution of the Lead Discovery Toolbox" can be accessed for free for a limited time at http://journals.sagepub.com/doi/full/10.1177/2472555218778503. For more information about SLAS and its journals, visit http://www.slas.org/journals.

About our Society and Journals

SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).

SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).

Follow SLAS on Twitter at @SLAS_Org.

Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.

Follow SLAS on YouTube at SLASvideo.

Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).

Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).

SLAS (Society for Laboratory Automation and Screening)

Related Drug Discovery Articles:

Choosing a simpler path to drug discovery
Researchers from Kyoto University, MIT, and ETH Zurich have developed a compact drug discovery method using simple models and small data sets.
Drug discovery researchers awarded grant to refine malaria drug
A research team from the Virginia Tech Center for Drug Discovery has received a $431,126 two-year grant from the National Institutes of Health to make improved versions of a promising compound called MMV008138, or 8138 for short.
New computational tool may speed drug discovery
A new computational tool called fABMACS is helping scientists see beyond static images of proteins to more efficiently understand how these molecules function, which could ultimately speed up the drug discovery process.
Paving the road to drug discovery
When treated with an anti-cancer drug, ICRF-193, fission yeast produce an 'arched and snapped' phenotype that may be used to screen for other cancer drugs.
Open-source drug discovery a success
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer.
Celgene joins DNDi's 'Drug Discovery Booster'
The biopharmaceutical company Celgene has become the fifth company to join the 'Neglected Tropical Diseases Drug Discovery Booster' consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world's most neglected diseases, leishmaniasis and Chagas disease.
Speeding up drug discovery to fight tuberculosis
Researchers at the Institute for Systems Biology and Center for Infectious Disease Research in Seattle have deciphered how the human pathogen Mycobacterium tuberculosis is able to tolerate the recently approved FDA drug bedaquiline.
Deep learning applied to drug discovery and repurposing
Scientists from Insilico Medicine in collaboration with Datalytic Solutions and Mind Research Network trained deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
Breast cancer drug discovery offers hope of new treatments
A new drug discovery approach has yielded a potential therapy for breast cancer that may be more effective than existing medicines.
Current cancer drug discovery method flawed: Study
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods.

Related Drug Discovery Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.